Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | IGF2BP1 | Q9NZI8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480971 | 0.98 | MAPK1 (0.35) | MAPK1KMT2AALDH1A1ATMRCE1 | |
| SCHEMBL6483175 | 0.83 | KMT2A (0.33) | KMT2AALDH1A1 | |
| SCHEMBL6482840 | 0.81 | MAPK1 (0.34) | MAPK1KMT2AALDH1A1ATMRCE1 | |
| SCHEMBL6491519 | 0.80 | POLB (0.34) | LMNASMN1; SMN2F10 | |
| SCHEMBL6481316 | 0.80 | MAPK1 (0.41) | MAPK1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL6492717 | 0.80 | MAPK1 (0.41) | MAPK1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6494841 | 0.78 | MAPK1 (0.34) | MAPK1ALDH1A1KDM4EL3MBTL1F10 | |
| SCHEMBL6480867 | 0.78 | MAPK1 (0.37) | MAPK1KMT2A | |
| SCHEMBL6491262 | 0.78 | POLB (0.34) | LMNASMN1; SMN2F10 | |
| SCHEMBL6482302 | 0.76 | MAPK1 (0.33) | MAPK1KMT2AALDH1A1ATMRCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050090398-A1 | Novel tetrazole derivative useful as herbicides | YANAGI AKIHIKO (JP) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | MAPK1 445/4885KMT2A 3201/4885ALDH1A1 4483/4885 |
| US-20050090398-A1 | Novel tetrazole derivative useful as herbicides | DDT, TTI1, CYP1A1 | MAPK1 2914/4885KMT2A 1800/4885ALDH1A1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.